dihexa human clinical trials data Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study Are Clinical Trial Diversity Initiatives

Alberti KGMM, Zimmet PZ

The absence of documented adverse events reflects the absence of studies, not proven safety

At 15 mg/mL (2.0 mL water), it equals approximately 17 units

No safety concerns were raised by clinical or laboratory assessments

BPC 157, in contrast, induced faster rates of healing and induced full functional restoration, which is also in agreement with the aforementioned studies on tendons (Krivic et al

Importantly, BPC-157 shows no direct angiogenic effect on endothelial cell cultures, suggesting its pro-angiogenic activity requires the context of injury and healing responses present in vivoa safety feature that may limit unwanted neovascularization in healthy tissues